Doxycycline: A pilot study to reduce diabetic proteinuria

American Journal of Nephrology

Volumn 27, Issue 3, 2007, Pages 269-273

  Naini, Afsoon Emami ^a   Harandi, Ali Amini ^a   Moghtaderi, Javad ^a   Bastani, Bahar ^b   Amiran, Ali ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetic nephropathy; Doxycycline; Metalloproteinase; Proteinuria

Indexed keywords

CREATININE; DOXYCYCLINE; POTASSIUM; SODIUM; ANTIINFECTIVE AGENT; MATRIX METALLOPROTEINASE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; PILOT STUDY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; SODIUM BLOOD LEVEL; STATISTICAL SIGNIFICANCE; UREA NITROGEN BLOOD LEVEL; URINE VOLUME; DRUG ANTAGONISM; DRUG EFFECT; EXTRACELLULAR MATRIX; MIDDLE AGED;

AGED; ANTI-BACTERIAL AGENTS; DIABETIC NEPHROPATHIES; DOXYCYCLINE; EXTRACELLULAR MATRIX; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PILOT PROJECTS; PROTEINURIA;

EID: 34250856233     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000101726     Document Type: Article

References (39)

1. Yee J: Plasma matrix metalloproteinase-9 and diabetic microalbuminuria: tip of the iceberg? Am J Kidney Dis 1998;32:669-671.
2. Marti HP: Role of matrix metalloproteinases in the progression of renal lesions. Presse Méd 2000;29:811-817.
3. Overall CM: Regulation of tissue inhibitor of matrix metalloproteinase expression. Ann NY Acad Sci 1994;732:51-64.
4. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T: Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998;12:12-26.
5. Sapadin AN, Fleischmajer R: Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad dermatol 2006;54:258-265.
6. Axisa B, Loftus IM, Naylor AR, Goodall S, Jones L, Bell PR, Thompson MM: Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 2002;33:2858-2864.
7. Novak MJ, Johns LP, Miller RC, Bradshaw MH: Adjunctive benefits of subantimicrobial dose doxycycline in the management of severe, generalized, chronic periodontitis. J Periodontol 2002;73:762-769.
8. Smith GN Jr, Mickler EA, Hasty KA, Brandt KD: Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme. Arthritis Rheum 1999;42:1140-1146.
9. Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, Ramamurthy NS: Minocycline reduces gingival collagenolytic activity during diabetes: preliminary observations and a proposed new mechanism of action. J Periodontal Res 1983;18:516-526.
10. Iwasaki H, Inoue H, Mitsuke Y, Badran A, Ikegaya S, Ueda T: Doxycycline induces apoptosis by way of caspase-3 activation with inhibition of matrix metalloproteinase in human T-lymphoblastic leukemia CCRF-CEM cells. J Lab Clin Med 2002;140:382-386.
11. Fife RS, Rougraff BT, Proctor C, Sledge GW Jr: Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells. J Lab Clin Med 1997;130:530-534.
12. Gilbertson-Beadling S, Powers EA, Stamp-Cole M, Scott PS, Wallace TL, Copeland J, Petzold G, Mitchell M, Ledbetter S, Poorman R: The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism. Cancer Chemother Pharmacol 1995;36:418-424.
13. Fife RS, Sledge GW Jr, Roth BJ, Proctor C: Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells. J Lab Clin Med 1995;125:407-411.
14. Seftor EA, Seftor RE, Nieva DR, Hendrix MJ: Application of chemically modified tetracyclines (CMTs) in experimental models of cancer and arthritis. Adv Dent Res 1998;12:103-110.
15. Smith GN Jr, Yu LP Jr, Brandt KD, Capello WN: Oral administration of doxycycline reduces collagenase and gelatinase activities in extracts of human osteoarthritic cartilage. J Rheumatol 1998;25:532-535.
16. Ahuja TS: Doxycycline decreases proteinuria in glomerulonephritis. Am J Kidney Dis 2003;42:376-380.
17. Chapman AB, Johnson AM, Gabow PA, Schrier RW: Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994;5:1349-1354.
18. Baxter BT, Pearce WH, Waltke EA, Littooy FN, Hallett JW Jr, Kent KC, Upchurch GR Jr, Chaikof EL, Mills JL, Fleckten B, Longo GM, Lee JK, Thompson RW: Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (phase II) multicenter study. J Vasc Surg 2002;36:1-12.
19. Davies M, Coles GA, Thomas GJ, Martin J, Lovett DH: Proteinases and the glomerulus: their role in glomerular diseases. Klin Wochenschr 1990;68:1145-1149.
20. Woessner JF Jr: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-2154.
21. Turck J, Pollock AS, Lovett DH: Gelatinase A is a glomerular mesangial cell growth and differentiation factor. Kidney Int 1997;51:1397-1400.
22. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V: Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997;277:225-228.
23. Senatorski G, Paczek L, Sulowicz W, Gradowska L, Bartlomiejczyk I: Urine activity of cathepsin B, collagenase and urine excretion of TGF-beta 1 and fibronectin in membranous glomerulonephritis. Res Exp Med (Berl) 1998;198:199-206.
24. Zaoui P, Cantin JF, Alimardani-Bessette M, Monier F, Halimi S, Morel F, Cordonnier D: Role of metalloproteases and inhibitors in the occurrence and progression of diabetic renal lesions. Diabetes Metab 2000;26(suppl 4):25-29.
25. Schnaper HW: Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis. Pediatr Nephrol 1995;9:104-111.
26. Fogo AB: Mesangial matrix modulation and glomerulosclerosis. Exp Nephrol 1999;7:147-159.
27. Kurogi Y: Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease. Med Res Rev 2003;23:15-31.
28. Shimamura T, Morrison AB: A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am J Pathol 1975;79:95-106.
29. Akiyama K, Shikata K, Sugimoto H, Matsuda M, Shikata Y, Fujimoto N, Obata K, Matsui H, Makino H: Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis. Res Commun Mol Pathol Pharmacol 1997;95:115-128.
30. Williamson JR, Tilton RG, Chang K, Kilo C: Basement membrane abnormalities in diabetes mellitus: relationship to clinical microangiopathy. Diabetes Metab Rev 1988;4:339-370.
31. Ziyadeh FN: Renal tubular basement membrane and collagen type IV in diabetes mellitus. Kidney Int 1993;43:114-120.
32. Brenner BM, Chertow GM: Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Dis 1994;23:171-175.
33. Brenner BM, Anderson S: The interrelationships among filtration surface area, blood pressure, and chronic renal disease. J Cardiovasc Pharmacol 1992;19(suppl 6):S1-S7.
34. Zheng F, Striker GE, Esposito C, Lupia E, Striker LJ: Strain differences rather than hyperglycemia determine the severity of glomerulosclerosis in mice. Kidney Int 1998;54:1999-2007.
35. Sharma K, Ziyadeh FN: The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 1994;266:F829-F842.
36. McMillan JI, Riordan JW, Couser WG, Pollock AS, Lovett DH: Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. J Clin Invest 1996;97:1094-1101.
37. Partridge CA, Jeffrey JJ, Malik AB: A 96-kD gelatinase induced by TNF-alpha contributes to increased microvascular endothelial permeability. Am J Physiol 1993;265:L438-L447.
38. Ebihara I, Nakamura T, Shimada N, Koide H: Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis 1998;32:544-550.
39. Steinmann-Niggli K, Ziswiler R, Kung M, Marti HP: Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis. J Am Soc Nephrol 1998;9:397-407.